Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

Immunotherapy Is Moving Forward in Bladder and Other GU Cancers

March 9th 2017

Charles Drake, M.D., Ph.D.. is optimistic about immunotherapy as it continues to move toward the frontline setting in GU cancers.

Avelumab Granted Priority Review by the FDA for Metastatic Urothelial Carcinoma

February 28th 2017

The FDA granted avelumab a priority review to a biologics license application to treat some patients with metastatic urothelial carcinoma, according to the developers of the drug.

Combination Regimen Benefits Genitourinary Cancers

February 25th 2017

Cabometyx combinations showed activity in patients with GU cancers, according to a preliminary clinical study.

Immunotherapy Duo Trumps Single Agent in Metastatic Bladder Cancer

February 23rd 2017

Patients with metastatic bladder cancer who did not see a benefit on single-agent Opdivo did better when the drug was combined with Yervoy, a recent study showed.

New Treatment Options Offer Hope in Bladder Cancer

February 21st 2017

Checkpoint inhibitors drastically changed the treatment landscape of urothelial carcinoma, and more changes are on the way.

Keytruda Granted Priority Review for Treatment of Urothelial Carcinoma

February 6th 2017

The FDA granted Keytruda a priority review for the treatment of some patients with urothelial carcinoma.

Opdivo Is Approved for Urothelial Carcinoma Subset

February 3rd 2017

Opdivo was granted an accelerated approval for a subset of patients with urothelial carcinoma.

A New Standard of Care for Advanced Urothelial Carcinoma

February 2nd 2017

After results from a phase 3 trial showed that Keytruda improved overall survival, it may become the next standard of care for patients with advanced urothelial carcinoma.

Antidiabetic Agent Linked to Increased Risk of Bladder Cancer

January 18th 2017

The FDA recently issued a warning that a type of medicine used to treat Type 2 diabetes may increase a person's risk for developing bladder cancer.

Tecentriq Gets FDA Priority Review for New Use In Bladder Cancer

January 10th 2017

Tecentriq (atezolizumab) is being reviewed for the use in additional settings to treat bladder cancer.

FDA Grants Durvalumab Priority Review for Bladder Cancer

December 31st 2016

The PD-L1 inhibitor durvalumab was granted a priority review for the treatment of some patients with urothelial carcinoma.

In the Age of Immunotherapy, Chemotherapy Is Still a Mainstay for Bladder Cancer

December 16th 2016

As immunotherapy's potential continues to grow in the treatment of bladder cancer, Gopa Iyer, M.D., says that more research needs to be done before it becomes the next new standard.

Bladder Cancer Treatments Continue to Evolve

December 9th 2016

The treatment landscape of bladder cancer drastically changed this spring with the approval of an immunotherapy agent, and will continue to shift in the months and years to come.

Popular Bladder Cancer Drug Production Halts, Worrying Patients, Physicians

December 1st 2016

One company's production of a popular bladder cancer therapy is set to halt by mid-2017, generating worries from patients and oncologists that there will be a shortage.

Immunotherapy Combination Shows Promise in Bladder Cancer

December 1st 2016

The combination of Opdivo and Yervoy is showing promise in the treatment of bladder cancer, according to a recent study.

Leveling the Playing Field for LGBT Patients

December 1st 2016

The National LGBT Cancer Network is making cancer screenings more available to a high-risk, underserved population.

Experts Discuss Immunotherapy's Role in the Shifting Landscape in Solid Tumors

November 30th 2016

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

Immunotherapy Will Be the Norm in Bladder Cancer Care

November 22nd 2016

When it comes to bladder cancer, PD-1 and PD-L1 agents will become the new mainstay, says Jonathan E. Rosenberg, M.D.

Anti-PD-1 Agent Improves Overall Survival in Bladder Cancer

November 15th 2016

According to results from a recent study, Keytruda had longer overall survival (OS) when compared to chemotherapy for patients with bladder cancer.

Using Biomarkers in Bladder Cancer Diagnosis and Monitoring

November 9th 2016

Biomarkers have value in the diagnosis and monitoring of bladder cancer, but their use is still being perfected.

Exploring Immunotherapy's Future in Bladder Cancer

November 7th 2016

Geoffrey Sklar, M.D. talks about the successes of immunotherapy agents like Opdivo, and where this research is moving in the field of bladder cancer.

Immunotherapy Agent Shows Promise in Advanced Bladder Cancer

November 2nd 2016

Opdivo had positive results in patients with advanced bladder cancer according to findings from the CheckMate-275 trial.

8 Questions With a Physician: Immunotherapy in Genitourinary Cancers

October 3rd 2016

There have been some exciting advances in using immunotherapy to treat GU malignancies such as kidney and bladder cancer. CURE sat down with Elizabeth Plimack, M.D. to discuss them.

Matthew Galsky Gives an Overview of Bladder Cancer

September 30th 2016

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Cystectomy to Treat Bladder Cancer: It's Complicated

September 28th 2016

Treating bladder cancer with a cystectomy may bring about some complicated side effects. Here are some resources to help.

Honing in on Bladder Cancer: Key Facts

September 28th 2016

CURE gathered some need-to-know facts about bladder cancer, the sixth most common cancer.

From Rags to Riches: Bladder Cancer Research Rife With New Approaches

September 27th 2016

For decades, research into bladder cancer treatments was stagnant, but now science has moved into a period rife with new approaches — immunotherapy chief among them.

Creating a Diversion: Life After Cystectomy for Bladder Cancer

September 22nd 2016

After the bladder is surgically removed and the urinary system diverted, most can return to their usual activities.

3 Questions: The Impact of Tecentriq to Treat Patients With Advanced Bladder Cancer

September 19th 2016

Tecentriq (atezolizumab) has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

Setback for Novel Agent to Treat Subset of Patients With Bladder Cancer

September 19th 2016

The FDA voted against approving Qapzola for treatment of some patients with bladder cancer.

NEXT PAGE
PREVIOUS PAGE